$109.26 Million in Sales Expected for Supernus Pharmaceuticals Inc (NASDAQ:SUPN) This Quarter
Wall Street analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce sales of $109.26 million for the current quarter, according to Zacks. Four analysts have made estimates for Supernus Pharmaceuticals’ earnings. The highest sales estimate is $111.45 million and the lowest is $106.20 million. Supernus Pharmaceuticals reported sales of $103.00 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The business is expected to announce its next quarterly earnings report on Tuesday, November 5th.
On average, analysts expect that Supernus Pharmaceuticals will report full-year sales of $414.98 million for the current fiscal year, with estimates ranging from $410.90 million to $419.58 million. For the next fiscal year, analysts forecast that the company will report sales of $451.75 million, with estimates ranging from $435.77 million to $466.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.05. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. The business had revenue of $104.70 million during the quarter, compared to the consensus estimate of $109.67 million. During the same quarter last year, the firm posted $0.57 EPS. Supernus Pharmaceuticals’s revenue was up 5.2% compared to the same quarter last year.
NASDAQ SUPN traded down $0.69 during mid-day trading on Monday, hitting $27.89. The company’s stock had a trading volume of 565,022 shares, compared to its average volume of 544,008. The company’s 50 day simple moving average is $28.86 and its 200 day simple moving average is $33.29. Supernus Pharmaceuticals has a twelve month low of $25.32 and a twelve month high of $51.38. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of 13.60, a PEG ratio of 0.99 and a beta of 1.62.
In other news, CEO Jack A. Khattar acquired 7,200 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $26.39 per share, with a total value of $190,008.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.57% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan boosted its holdings in Supernus Pharmaceuticals by 2.2% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 15,650 shares of the specialty pharmaceutical company’s stock worth $518,000 after acquiring an additional 330 shares during the last quarter. Bridge City Capital LLC raised its stake in shares of Supernus Pharmaceuticals by 0.5% during the 2nd quarter. Bridge City Capital LLC now owns 69,000 shares of the specialty pharmaceutical company’s stock worth $2,283,000 after purchasing an additional 338 shares during the period. Oregon Public Employees Retirement Fund raised its stake in shares of Supernus Pharmaceuticals by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 20,239 shares of the specialty pharmaceutical company’s stock worth $709,000 after purchasing an additional 366 shares during the period. Baltimore Washington Financial Advisors Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.9% during the 2nd quarter. Baltimore Washington Financial Advisors Inc. now owns 45,033 shares of the specialty pharmaceutical company’s stock worth $1,490,000 after purchasing an additional 420 shares during the period. Finally, Diversified Trust Co raised its stake in shares of Supernus Pharmaceuticals by 8.4% during the 2nd quarter. Diversified Trust Co now owns 6,450 shares of the specialty pharmaceutical company’s stock worth $213,000 after purchasing an additional 500 shares during the period. 99.35% of the stock is currently owned by hedge funds and other institutional investors.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Featured Article: What is Green Investing?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.